Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study.
Azathioprine
Crohn's Disease
Inflammatory bowel diseases
Relapse
Side effects
Ulcerative Colitis
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
received:
27
03
2023
revised:
04
06
2023
accepted:
03
07
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
There is no consensus on the recommended duration of and optimal time to stop azathioprine (AZA) therapy in inflammatory bowel disease (IBD). Determining the optimal duration and cessation time can help to balance the risks of long-term intake with the possibility of relapse after cessation. To describe the events following AZA cessation. Retrospective analysis was performed to examine data from adult patients affected by IBD who were followed at the University of Padua and had started but then discontinued AZA between 1995 and 2022. Data on therapy duration, reasons for cessation, and type of relapse after cessation were collected. Cox regression models were used to estimate the risk of relapse in different subgroups. A total of 133 ulcerative colitis patients and 141 Crohn's disease patients were included. Therapy with AZA was stopped in the 1 AZA administration is effective and safe, but it requires careful monitoring for potential minor and major side effects. Only 10% of patients who achieved remission with AZA needed a new treatment within 1 year of drug interruption.
Sections du résumé
BACKGROUND
BACKGROUND
There is no consensus on the recommended duration of and optimal time to stop azathioprine (AZA) therapy in inflammatory bowel disease (IBD). Determining the optimal duration and cessation time can help to balance the risks of long-term intake with the possibility of relapse after cessation.
AIM
OBJECTIVE
To describe the events following AZA cessation.
METHODS
METHODS
Retrospective analysis was performed to examine data from adult patients affected by IBD who were followed at the University of Padua and had started but then discontinued AZA between 1995 and 2022. Data on therapy duration, reasons for cessation, and type of relapse after cessation were collected. Cox regression models were used to estimate the risk of relapse in different subgroups.
RESULTS
RESULTS
A total of 133 ulcerative colitis patients and 141 Crohn's disease patients were included. Therapy with AZA was stopped in the 1
CONCLUSION
CONCLUSIONS
AZA administration is effective and safe, but it requires careful monitoring for potential minor and major side effects. Only 10% of patients who achieved remission with AZA needed a new treatment within 1 year of drug interruption.
Identifiants
pubmed: 37545640
doi: 10.3748/wjg.v29.i27.4334
pmc: PMC10401657
doi:
Substances chimiques
Azathioprine
MRK240IY2L
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4334-4343Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Références
Expert Rev Clin Immunol. 2017 Sep;13(9):877-888
pubmed: 28678626
Semin Pediatr Surg. 2017 Dec;26(6):349-355
pubmed: 29126502
BMJ. 1992 Jul 4;305(6844):20-2
pubmed: 1638191
Lancet. 1978 Nov 4;2(8097):955-7
pubmed: 81986
Lancet. 2012 Nov 3;380(9853):1590-605
pubmed: 22914295
Cochrane Database Syst Rev. 2018 May 12;5:CD012540
pubmed: 29756637
J Crohns Colitis. 2022 Aug 4;16(7):1011-1019
pubmed: 35134140
Aliment Pharmacol Ther. 2014 Dec;40(11-12):1313-23
pubmed: 25284134
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Am J Gastroenterol. 2008 Jul;103(7):1783-800
pubmed: 18557712
Clin Gastroenterol Hepatol. 2010 Mar;8(3):268-74
pubmed: 20005977
Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43
pubmed: 15354273
Am J Epidemiol. 2013 Jun 1;177(11):1296-305
pubmed: 23514635
Frontline Gastroenterol. 2020 Jun 11;12(5):423-436
pubmed: 35401955
Inflamm Intest Dis. 2021 Aug 18;7(1):7-12
pubmed: 35224012
World J Gastroenterol. 2023 Mar 7;29(9):1536-1538
pubmed: 36998430
Cochrane Database Syst Rev. 2016 May 18;(5):CD000478
pubmed: 27192092
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
Dig Dis. 2010;28(3):508-18
pubmed: 20926880
Cochrane Database Syst Rev. 2000;(2):CD000067
pubmed: 10796482
Drug Des Devel Ther. 2011 Apr 06;5:185-210
pubmed: 21552489
Gastroenterology. 2004 May;126(6):1504-17
pubmed: 15168363
Dig Dis Sci. 2006 Sep;51(9):1516-24
pubmed: 16927148
Lancet. 1994 May 21;343(8908):1249-52
pubmed: 7910274
J Crohns Colitis. 2014 Oct;8(10):1179-207
pubmed: 24909831
J Pediatr Gastroenterol Nutr. 2018 Aug;67(2):257-291
pubmed: 30044357
Gastroenterology. 2005 Jun;128(7):1812-8
pubmed: 15940616
Am J Gastroenterol. 2009 Nov;104(11):2760-7
pubmed: 19623172
Dig Dis Sci. 2019 Jun;64(6):1612-1621
pubmed: 30604371
Eur Rev Med Pharmacol Sci. 2014;18(2):165-70
pubmed: 24488903
Am J Gastroenterol. 2010 Jul;105(7):1604-9
pubmed: 20104215
Aliment Pharmacol Ther. 2004 Jun 1;19(11):1147-52
pubmed: 15153167
J Crohns Colitis. 2022 Jan 28;16(1):2-17
pubmed: 34635919
Cochrane Database Syst Rev. 2000;(2):CD000545
pubmed: 10796557
Clin Gastroenterol Hepatol. 2021 Apr;19(4):713-720.e1
pubmed: 32272248
Clin Pharmacokinet. 2007;46(3):187-208
pubmed: 17328579
Dig Dis Sci. 2015 May;60(5):1414-23
pubmed: 25381202
Curr Treat Options Gastroenterol. 2017 Mar;15(1):84-104
pubmed: 28160250
Dis Mon. 2018 Feb;64(2):20-57
pubmed: 28826742
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174